Additionally, bone metabolism-related biomarkers showed only a significant positive correlation with PTH levels.<h4>Conclusions</h4>Everolimus treatment did not modify the clinical progression of the disease in an aggressive form of POH, although an impact on the protein markers studied was observed. This evidence concerns the gene PTH and progressive osseous heteroplasia.